Search results
Results from the WOW.Com Content Network
Bone: alendronate has been linked in long-term users to the development of low-impact femoral fractures. [15] Further, studies suggest that users of alendronate have an increase in the numbers of osteoclasts and develop giant, more multinucleated osteoclasts; the significance of this development is unclear. [16]
Alendronic acid/colecalciferol, sold under the brand name Fosamax Plus D among others, is a medication for the treatment of osteoporosis in men or in postmenopausal women. [3] [2] [4] [6]
Subjects (n=1139) received additional 2 years of 70 mg of alendronate, Vitamin D (400 to 800 IU), and calcium (500–1000 mg) supplementation daily. Combined abaloparatide and alendronate therapy reduced significantly the incidence of vertebral and nonvertebral fractures.
This page was last edited on 4 July 2008, at 16:41 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply ...
Ibandronic acid is a bisphosphonate medication used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer. [4] It may also be used to treat hypercalcemia (elevated blood calcium levels).
1,25 dihydroxycholecalciferol 1-Day 1-deamino-8-d-arginine vasopressin 13-cis-retinoic acid 2'-deoxycoformycin 2-amino-6-mercaptopurine 2-amino-6-trifluoromethoxy-benzothiazole 2-CdA 2-chlorodeoxyadenosine 2-PAM 2-propylpentanoic acid 2-propylvaleric acid 2-pyridine aldoxime methochloride 292 MEP 311C90 3M Avagard (Discontinued) 3M Cavilon Skin ...
This type of drug has a high affinity for hydroxyapatite [28] and stays in bone tissue for a long period of time, [29] with alendronate, it has a half-life of approximately ten years. [30] The risk of a patient having MRONJ after discontinuing this medication is unknown. [30]
In 2017, a large study of over 280,000 British and Spanish patients found no increased risk of venous thromboembolism in users of strontium ranelate compared to alendronate. [5] Servier ceased manufacturing the drug and in 2019, the drug returned the market in the United Kingdom under the name strontium ranelate Aristo. [6]